Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Asset Writedowns and Impairment (2024)

Regenxbio (RGNX) has 1 years of Asset Writedowns and Impairment data on record, last reported at $1.4 million in Q2 2024.

  • For Q2 2024, Asset Writedowns and Impairment changed N/A year-over-year to $1.4 million; the TTM value through Dec 2024 reached $2.1 million, changed N/A, while the annual FY2024 figure was $2.1 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $1.4 million in Q2 2024 per RGNX's latest filing, up from $700000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q2 2024 and bottomed at $700000.0 in Q1 2024.